The pharmaceutical industry has suggested to the central government that it should increase its reviewing powers on the decisions taken by National Pharmaceutical Pricing Authority (NPPA). The regulator is learnt to have responded with a contrarian view that the government should “abandon its archaic practice of reviewing NPPA orders” and, instead, establish an independent appellate tribunal. At an interaction with government officials, the pharmaceutical industry also suggested that it should have a representation in NPPA meetings, a request that was rejected outright by the Department of Pharmaceuticals (DoP) on the grounds that this request will generate a “conflict of interest”.